Loading
Abalos Therapeutics is testing a modified virus, given into a vein, that is designed to switch on the immune system inside tumours without destroying the infected cells. Its first medicine, ABX-001, is in an early trial for people with advanced solid tumours.
Abalos Therapeutics GmbH, based in Düsseldorf, Germany, develops arenavirus-based immunotherapies built on lymphocytic choriomeningitis virus (LCMV), which it describes as a non-lytic viroimmunotherapy that replicates in cancer cells and antigen-presenting cells to trigger innate and adaptive immune responses inside the tumour (its AdaptInnate approach). The lead candidate ABX-001 entered a first-in-human, open-label, dose-escalation phase 1 study given as a single intravenous dose in about 18 patients with refractory or relapsed advanced solid tumours (EUCT 2024-512403-39-01); the company announced the first patient dosed on 23 October 2025. The ClinicalTrials.gov record, NCT07231458, also covers ABX-001 combined with pembrolizumab. Its first registered cancer trial, NCT07231458, was posted on ClinicalTrials.gov in November 2025. The company launched in October 2019 with a EUR 12 million Series A, and an extension led by Seventure Partners in October 2021 brought the Series A to EUR 43 million (USD 50 million); other investors named by the company include Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, NRW.BANK, Gründerfonds Ruhr, Coparion and Hx Bio Ventures. It also received EUR 1.2 million from Germany's KMU-innovativ programme.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A extension · EUR 32.5 million extension led by Seventure Partners bringing the Series A total to EUR 43 million (USD 50 million); the USD figure is the round total stated in the release. | 2021 | $50M | abalos-tx.com |
| Series A · EUR 12 million launch round, as titled on the company's news page. | 2019 | undisclosed | abalos-tx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/